Cochrane Abstracts
Alemtuzumab for multiple sclerosis
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Alemtuzumab for Multiple Sclerosis." Cochrane Abstracts, John Wiley & Sons, Inc, 2024. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/431525/all/Alemtuzumab_for_multiple_sclerosis.
Alemtuzumab for multiple sclerosis. Cochrane Abstracts. John Wiley & Sons, Inc; 2024. https://evidence.unboundmedicine.com/evidence/view/Cochrane/431525/all/Alemtuzumab_for_multiple_sclerosis. Accessed November 21, 2024.
Alemtuzumab for multiple sclerosis. (2024). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/431525/all/Alemtuzumab_for_multiple_sclerosis
Alemtuzumab for Multiple Sclerosis [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2024. [cited 2024 November 21]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/431525/all/Alemtuzumab_for_multiple_sclerosis.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Alemtuzumab for multiple sclerosis
ID - 431525
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/431525/all/Alemtuzumab_for_multiple_sclerosis
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
